Background Hepatitis C virus (HCV) infection in Egypt is the highest in the world. The goals of HCV treatment are to eliminate the infection and reducing its consequences. With the highly effective oral antiviral regimens for chronic hepatitis C (CHC), most cases can reach sustained virological response (SVR).
Aim This study aimed to evaluate direct acting antivirals (DAAs) in HCV treatment among patients with CHC infection by investigating the SVR12.
Methods This cross-section study was carried out on 127 CHC patients receiving DDAs. They were subjected to quantitative determination of HCV-RNA by RT-PCR at start of treatment and after 12 weeks from the end of the therapy to assess the SVR.
Results Among those patients, 126 (99.2%) were responders meeting the criteria of SVR12, and only one patient (0.8%) was non-responder. The latter was 58 years old female. She had high baseline HCV RNA level of 2.3×106 IU/ml, non-cirrhotic and had fatty liver. She was negative for HBsAg and HIV. The patient had experienced treatment failure in previous IFN-based therapeutic regimen. She received SOF + DAC + RBV regimen. There was a statistically significant decrease in ALT, AST and hemoglobin levels and a significant increase in total and direct bilirubin levels after treatment when compared with their levels before treatment.
Conclusion There was a high achievement of SVR12 indicating high effectiveness of DAAs treatment regimens.